EGFR and non-small cell squamous lung carcinoma: A phase I study NCT03050411 aims to evaluate the dosage and efficacy of apatinib, a TKI that selectively inhibits VEGFR-2, when given in combination with EGFR-TKI in the treatment of EGFR-TKI-resistant advanced non-squamous non-small cell lung cancer.